Loading...
•
Dec 31, 2025
CryoPort Q4 2025 Earnings Report
Cryoport reported higher revenue in Q4 2025 with improved gross margin and a narrower net loss year-over-year.
Key Takeaways
Cryoport generated 10% year-over-year revenue growth in Q4 2025, driven by strength in Life Sciences Services, while gross margin expanded and net loss significantly narrowed compared to the prior year period.
Total revenue increased 10% year-over-year to 45450000 in Q4 2025.
Life Sciences Services revenue grew 16% year-over-year, led by BioStorage/BioServices growth of 18%.
Gross margin improved to 47.8% from 47.0% in the prior year quarter.
Net loss attributable to common stockholders narrowed to 13644000 from 20669000 year-over-year.
Revenue by Segment
Forward Guidance
For full-year 2026, Cryoport expects revenue between 190000000 and 194000000, representing anticipated year-over-year growth of 8% to 10%.
Positive Outlook
- Revenue guidance implies continued year-over-year growth.
- Expected 13 BLA/MAA application filings in 2026.
- Anticipation of nine new therapy approvals.
- Additional two approvals for label or geographic expansions.
- Strategic partnership with DHL expected to enhance EMEA and APAC positioning.
Challenges Ahead
- Guidance subject to macroeconomic and geopolitical uncertainty.
- Potential supply chain constraints and inflationary pressures.
- Exposure to foreign currency fluctuations.
- Risk of U.S. federal government shutdown impact.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...